Rigel Pharmaceuticals (RIGL)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Rigel Pharmaceuticals chart...

About the Company

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

CEO

Raul Rodriguez

Exchange

NASDAQ

Website

https://www.rigel.com/

$85M

Total Revenue

280

Employees

$234M

Market Capitalization

-8.69

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RIGL News

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

6d ago, source:

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President ...

Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),

12d ago, source:

Key Insights Significantly high institutional ownership implies Rigel Pharmaceuticals' stock price is sensitive ...

RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023

13d ago, source:

Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the fourth ...

Rigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39M

on MSN ago, source:

Q4 GAAP EPS of $0.00 beats by $0.02. Revenue of $35.8M (-30.2% Y/Y) beats by $2.39M. Fourth quarter 2023 Total Revenue of ...

Rigel Pharmaceuticals files patent for pyrazole compound for inhibiting IRAK protein in subjects

7d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Rigel Pharmaceuticals for a compound targeting IRAK proteins to treat a wide range of diseases. Learn more about its potential in autoimmune, inflammatory, ...

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript

13d ago, source: Seeking Alpha

Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023. At this time, all participants are in a listen-only mode. A brief question-and ...

Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer

6d ago, source: Nasdaq

(RTTNews) - Tuesday, Rigel Pharmaceuticals, Inc. (RIGL) appointed Lisa Rojkjaer, as executive vice president and chief medical officer. Rojkjaer, a board-certified hematologist with an ...

Rigel Pharmaceuticals names new Chief Medical Officer

6d ago, source: Investing

SOUTH SAN FRANCISCO, Calif. - Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (NASDAQ:RIGL) has announced the appointment of Lisa Rojkjaer, M.D., as its new Executive Vice President and Chief Medical ...

Rigel Pharmaceuticals: Q4 Earnings Insights

13d ago, source:

Rigel Pharmaceuticals RIGL reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Rigel Pharmaceuticals beat estimated ...

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

6d ago, source: Morningstar

SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief ...

Rigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

6d ago, source:

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...